As of July 2020, American biopharmaceutical company Gilead Sciences expected that they will produce more than two million treatment courses of their antiviral drug remdesivir by the end of the year in order to meet the global real-time need. This statistic depicts the cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020.
Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020
(in 1,000s)
Characteristic
Cumulative treatment courses in thousands
December
2,000
July
288
June
190
April
30
January
5
05001,0001,5002,0002,500
Add this content to your personal favorites. These can be accessed from the favorites menu in the main navigation.
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Original manufacturing projections from January to May based on 11-vial treatment course. Projections through end of June based on average 7.78 vials per treatment course. Year-end projection based on average 6.25 vials per treatment course.
Figures reflect the cumulative amount of drug that Gilead expects to produce and are inclusive of supply allocated for clinical trials, compassionate use and expanded access programs, and any potential regulatory authorizations or approvals.
Learn more about how Statista can support your business.
Evaluate Vantage. (July 31, 2020). Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s) [Graph]. In Statista. Retrieved May 08, 2025, from https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
Evaluate Vantage. "Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s)." Chart. July 31, 2020. Statista. Accessed May 08, 2025. https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
Evaluate Vantage. (2020). Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s). Statista. Statista Inc.. Accessed: May 08, 2025. https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
Evaluate Vantage. "Cumulative Amount of Remdesivir Treatment Courses Projected to Be Manufactured by Gilead Sciences during 2020 (in 1,000s)." Statista, Statista Inc., 31 Jul 2020, https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
Evaluate Vantage, Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s) Statista, https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/ (last visited May 08, 2025)
Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020 (in 1,000s) [Graph], Evaluate Vantage, July 31, 2020. [Online]. Available: https://www.statista.com/statistics/1143013/remdesivir-manufacturing-projections/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
